Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024
Bionomics (Nasdaq: BNOX), a clinical-stage biotechnology company, has announced a corporate update and discussion of end-of-Phase 2 (EoP2) meeting outcomes with the FDA regarding the advancement of BNC210 for post-traumatic stress disorder (PTSD) treatment into Phase 3. The update will be provided on July 31, 2024, at 8:00 am ET via a conference call and webcast presentation.
Interested parties can access the call using the provided toll-free and international numbers, along with the conference ID. A webcast link is also available, and a replay will be posted on Bionomics' website Events page under the Investors section after the presentation.
Bionomics (Nasdaq: BNOX), un'azienda biotecnologica in fase clinica, ha annunciato un aggiornamento aziendale e una discussione sui risultati dell'incontro End-of-Phase 2 (EoP2) con la FDA riguardo all'avanzamento di BNC210 per il trattamento del disturbo da stress post-traumatico (PTSD) verso la Fase 3. L'aggiornamento sarà fornito il 31 luglio 2024, alle 8:00 ET tramite una teleconferenza e una presentazione in webcast.
Le parti interessate possono accedere alla chiamata utilizzando i numeri internazionali e toll-free forniti, insieme all'ID della conferenza. È anche disponibile un link per il webcast, e una registrazione sarà pubblicata sulla pagina Eventi del sito web di Bionomics nella sezione Investitori dopo la presentazione.
Bionomics (Nasdaq: BNOX), una empresa biotecnológica en etapa clínica, ha anunciado una actualización corporativa y una discusión sobre los resultados de la reunión de End-of-Phase 2 (EoP2) con la FDA en relación con el avance de BNC210 para el tratamiento del trastorno de estrés postraumático (PTSD) hacia la Fase 3. La actualización se proporcionará el 31 de julio de 2024, a las 8:00 a.m. ET a través de una llamada de conferencia y una presentación por webcast.
Las partes interesadas pueden acceder a la llamada utilizando los números gratuitos e internacionales proporcionados, junto con el ID de la conferencia. También hay un enlace para el webcast disponible, y una repetición se publicará en la página de Eventos del sitio web de Bionomics en la sección de Inversores después de la presentación.
Bionomics (Nasdaq: BNOX)는 임상 단계 생명공학 회사로서, PTSD(외상후 스트레스 장애) 치료를 위한 BNC210의 3상 진입에 관한 FDA와의 제2단계 종료(EoP2) 회의 결과에 대한 기업 업데이트와 논의를 발표했습니다. 업데이트는 2024년 7월 31일 오전 8시 ET에 전화 회의 및 웹캐스트 프레젠테이션을 통해 제공될 예정입니다.
관심 있는 분들은 제공된 무료 및 국제 전화번호 그리고 회의 ID를 사용하여 통화에 접근할 수 있습니다. 또한 웹캐스트 링크도 제공되며, 프레젠테이션 이후 Bionomics의 웹사이트 이벤트 페이지 투자자 섹션에 재생 기록이 게시될 것입니다.
Bionomics (Nasdaq: BNOX), une entreprise de biotechnologie en phase clinique, a annoncé une mise à jour de l'entreprise et une discussion sur les résultats de la réunion de fin de phase 2 (EoP2) avec la FDA concernant l'avancement de BNC210 pour le traitement du trouble de stress post-traumatique (TSPT) vers la phase 3. La mise à jour sera fournie le 31 juillet 2024 à 8h00 ET lors d'un appel conférence et d'une présentation en webcast.
Les parties intéressées peuvent accéder à l'appel en utilisant les numéros internationaux et gratuits fournis, ainsi que l'ID de la conférence. Un lien pour le webcast est également disponible, et un replay sera publié sur la page Événements du site web de Bionomics dans la section Investisseurs après la présentation.
Bionomics (Nasdaq: BNOX), ein biopharmazeutisches Unternehmen in klinischen Studien, hat ein Unternehmensupdate und eine Diskussion über die Ergebnisse des End-of-Phase 2 (EoP2) Meetings mit der FDA bezüglich des Fortschritts von BNC210 zur Behandlung von posttraumatischen Belastungsstörungen (PTBS) in die Phase 3 angekündigt. Das Update wird am 31. Juli 2024 um 8:00 Uhr ET über einen Konferenzanruf und eine Webcast-Präsentation bereitgestellt.
Interessierte Parteien können die Sitzung über die bereitgestellten gebührenfreien und internationalen Telefonnummern sowie die Konferenz-ID erreichen. Ein Webcast-Link ist ebenfalls verfügbar, und eine Aufzeichnung wird nach der Präsentation auf der Veranstaltungsseite der Bionomics-Website im Bereich Investoren veröffentlicht.
- Advancement of BNC210 for PTSD treatment to Phase 3 clinical trials
- Scheduled corporate update and discussion of FDA meeting outcomes
- Investor engagement through conference call and webcast presentation
- None.
ADELAIDE, Australia and CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will provide a corporate update and discuss the outcomes of an end-of-Phase 2 (EoP2) meeting with the U.S. Food and Drug Administration regarding the advancement of BNC210 for the treatment of post-traumatic stress disorder (PTSD) into Phase 3 on Wednesday, July 31 at 8:00 am ET.
Conference Call and Webcast Presentation
Date and Time: Wednesday, July 31, 2024 at 8:00 a.m. ET
Toll Free: 1-877-407-0792
International: 1-201-689-8263
Conference ID: 13748183
Webcast Presentation: Click here
A replay of the webcast, when available, will be posted to Bionomics’ website Events page under the Investors section.
FOR FURTHER INFORMATION PLEASE CONTACT:
| General Rajeev Chandra Company Secretary CoSec@bionomics.com.au | Investor Relations Kevin Gardner kgardner@lifesciadvisors.com | Investor Relations Chris Calabrese ccalabrese@lifesciadvisors.com |
About Bionomics Limited
Bionomics (NASDAQ: BNOX) is a clinical-stage biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder (SAD) and chronic treatment of post-traumatic stress disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other CNS conditions. Bionomics’ pipeline also includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels being developed for CNS conditions of high unmet need. www.bionomics.com.au
FAQ
What is the purpose of Bionomics' upcoming corporate update on July 31, 2024?
When and how can investors access Bionomics' (BNOX) corporate update presentation?
What is BNC210 and what stage of development is it in for PTSD treatment?
Will there be a replay available for Bionomics' (BNOX) July 31, 2024 corporate update?
